MedTrace Logo

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

NCT02472977 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2018-11-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.

Conditions

Interventions

DRUG

Ulocuplumab

DRUG

Nivolumab

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-13
Primary Completion
2017-01-27
Completion
2017-01-27
FDA Drug
Yes

Countries

  • United States
  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02472977 on ClinicalTrials.gov